CN106606744A - Combination medicament for treating type 2 diabetes mellitus - Google Patents
Combination medicament for treating type 2 diabetes mellitus Download PDFInfo
- Publication number
- CN106606744A CN106606744A CN201710076490.7A CN201710076490A CN106606744A CN 106606744 A CN106606744 A CN 106606744A CN 201710076490 A CN201710076490 A CN 201710076490A CN 106606744 A CN106606744 A CN 106606744A
- Authority
- CN
- China
- Prior art keywords
- parts
- leaves
- diabetes
- sweet potato
- acacia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 27
- 244000017020 Ipomoea batatas Species 0.000 claims abstract description 20
- 235000002678 Ipomoea batatas Nutrition 0.000 claims abstract description 20
- 240000007472 Leucaena leucocephala Species 0.000 claims abstract description 20
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims abstract description 20
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 20
- 241000124033 Salix Species 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 241001061264 Astragalus Species 0.000 claims abstract description 13
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 13
- 244000234609 Portulaca oleracea Species 0.000 claims abstract description 13
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 13
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 13
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 13
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 13
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 13
- 235000006533 astragalus Nutrition 0.000 claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 claims abstract description 13
- 210000004233 talus Anatomy 0.000 claims abstract description 13
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 12
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 12
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 12
- 244000182216 Mimusops elengi Species 0.000 claims abstract 3
- 241000220259 Raphanus Species 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 14
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 12
- 241000830535 Ligustrum lucidum Species 0.000 claims description 12
- 241000245665 Taraxacum Species 0.000 claims description 12
- 235000003373 curcuma longa Nutrition 0.000 claims description 12
- 235000013976 turmeric Nutrition 0.000 claims description 12
- 239000003205 fragrance Substances 0.000 claims description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 10
- 239000010931 gold Substances 0.000 claims description 10
- 229910052737 gold Inorganic materials 0.000 claims description 10
- 244000241838 Lycium barbarum Species 0.000 claims description 2
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 3
- 244000163122 Curcuma domestica Species 0.000 claims 3
- 239000009636 Huang Qi Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 241000735234 Ligustrum Species 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000088415 Raphanus sativus Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 240000005373 Panax quinquefolius Species 0.000 description 10
- 244000008991 Curcuma longa Species 0.000 description 9
- 240000002624 Mespilus germanica Species 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 7
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 2
- 208000026292 Cystic Kidney disease Diseases 0.000 description 2
- 241000756042 Polygonatum Species 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940103453 novolin Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 241001633583 Adenophora Species 0.000 description 1
- 241000605447 Anemarrhena Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000096284 Gynochthodes officinalis Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019646 Hepatic cyst Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 240000001740 Momordica dioica Species 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000036741 Pruritus generalised Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229930191283 anemarrhena Natural products 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/09—Lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗Ⅱ型糖尿病的组合药物,是由黄芪、人参、女贞子、枸杞子、焦白术、熟地、葛根、郁金、鸡内金、马齿苋、蒲公英、木香、地衣、白萝卜、红薯叶、柳叶、洋槐叶16味种草药材制成,该组合药物能够清热解郁,除去瘀积,正本清源,使患者肌体强健如初,糖尿病可得根治,并收到见效快、疗程短治愈率高、复发率低的疗效。The invention discloses a combined medicine for treating type Ⅱ diabetes, which is composed of astragalus, ginseng, privet fruit, medlar, Jiaobaizhu, rehmannia glutinosa, kudzu root, curcuma, gallinacea, purslane, dandelion, wood It is made of 16 kinds of herbal medicines such as incense, lichen, white radish, sweet potato leaf, willow leaf and acacia leaf. It has the curative effect of quick effect, short course of treatment, high cure rate and low recurrence rate.
Description
技术领域technical field
本发明属于中药技术领域,特别涉及一种用于治疗Ⅱ型糖尿病的组合药物。The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a combination medicine for treating type II diabetes.
背景技术Background technique
糖尿病(中医谓之消渴)是目前社会比较常见的疾病,而且随着生活水平的提高,糖尿病的发病率越来越高。西医认为,糖尿病是由于体内胰岛素缺乏或胰岛素在靶细胞不能发挥正常生理作用而引起的糖、蛋白、及脂肪代谢紊乱的一种综合症。糖尿病的基本特征是长期高血糖,可以损害全身多个系统,主要损害心血管系统,久病还可导致眼、肾、神经、心脏、血管等组织的慢性进行性病变,引起功能缺陷及衰竭。糖尿病的症状可分为两大类:一大类是与代谢紊乱有关的表现,尤其是与高血糖有关的“三多一少”,多见于Ⅰ型糖尿病;Ⅱ型糖尿病常不十分明显或仅有部分表现。Ⅱ型糖尿病人血糖升高主要是因为胃肠吸收来的糖不能及时送到四肢、皮肤等外周部位,这些部位的细胞不能充分地消耗血糖,参与消耗血糖的细胞数量减少,最后导致血糖的升高。Diabetes (known as diabetes in Chinese medicine) is a relatively common disease in society at present, and with the improvement of living standards, the incidence of diabetes is getting higher and higher. Western medicine believes that diabetes is a syndrome of sugar, protein, and fat metabolism disorders caused by the lack of insulin in the body or the inability of insulin to play a normal physiological role in target cells. The basic feature of diabetes is long-term high blood sugar, which can damage multiple systems of the body, mainly the cardiovascular system. Prolonged illness can also lead to chronic progressive lesions in the eyes, kidneys, nerves, heart, blood vessels and other tissues, causing functional defects and failure. The symptoms of diabetes can be divided into two categories: a large category is related to metabolic disorders, especially "three more and one less" related to hyperglycemia, which is more common in type 1 diabetes; type 2 diabetes is often not very obvious or only There are partial performances. The main reason for the increase in blood sugar in type 2 diabetes is that the sugar absorbed by the gastrointestinal tract cannot be sent to peripheral parts such as limbs and skin in time. high.
传统学说认为糖尿病的病因与以下三种因素有关:1.遗传因素,糖尿病是遗传性疾病,遗传学研究表明,糖尿病发病率在血统亲属中与非血统亲属中有显著差异,前者较后者高出5倍左右。在Ⅰ型糖尿病的病因中遗传因素的重要性为50%左右,而在Ⅱ型糖尿病的病因中遗传因素的重要性达90%以上;2.精神因素,近时期以来,中、外学者确认了精神因素在糖尿病发生、发展中的作用,认为伴随着精神的紧张、情绪的激动及各种应激状态,会引起升高血糖激素的大量分泌,如生长激素、去甲肾上腺素、胰升糖素及肾上腺皮质激素等;3.肥胖因素,目前认为,肥胖是糖尿病的一个重要诱发因素,60%-80%的成年糖尿病患者在发病之前均为肥胖者,肥胖的程度与糖尿病的发病率呈正比,而且随着年龄的增长,体力活动逐渐减少时,人体肌肉与脂肪的比例也在改变,自25岁至75岁,肌肉组织逐渐减少,由占体重的47%减少到36%,而脂肪由20%增加到36%,这是老年人,特别是肥胖多脂肪的老年人中糖尿病明显增多的主要原因之一;4.长期摄食过多,饮食过多而不节制,营养过剩,使原已潜在的功能低下的胰岛素β细胞负担过重,而诱发糖尿病。现在国内外已形成了“生活越富裕,身体越丰满,糖尿病越增多”的概念。The traditional theory believes that the cause of diabetes is related to the following three factors: 1. Genetic factors. Diabetes is a hereditary disease. Genetic studies have shown that the incidence of diabetes is significantly different between blood relatives and non-blood relatives, and the former is higher than the latter. Out about 5 times. The importance of genetic factors in the etiology of type 1 diabetes is about 50%, while the importance of genetic factors in the etiology of type 2 diabetes is more than 90%; 2. Mental factors have been confirmed by Chinese and foreign scholars in recent times The role of mental factors in the occurrence and development of diabetes is believed to be accompanied by mental tension, emotional agitation and various stress states, which will cause a large amount of secretion of blood sugar-raising hormones, such as growth hormone, norepinephrine, and glucagon. 3. Obesity factors. At present, it is believed that obesity is an important inducing factor of diabetes. 60%-80% of adult diabetic patients are obese before the onset of diabetes. The degree of obesity is positively related to the incidence of diabetes. And with the increase of age, when physical activity gradually decreases, the ratio of human muscle to fat is also changing. From 25 to 75 years old, muscle tissue gradually decreases from 47% to 36% of body weight, while fat Increased from 20% to 36%, which is one of the main reasons for the obvious increase of diabetes in the elderly, especially the obese and fat elderly; Diabetes is induced by overburdening the potentially hypofunctioning insulin β-cells. At present, the concept of "the richer the life, the fuller the body, the more diabetes will increase" has been formed at home and abroad.
目前,国内外对糖尿病的治疗分为中医治疗和西医治疗两种,西药主要靠胰岛素,用药时间长,副作用大,微血管可发生病变;用双胍类药物,疗效低,副作用大。我国中医治疗糖尿病有悠久的历史,近时期以来,越累越多的中药方剂公开于世,但纵观这些技术,绝大多数以解决糖尿病阴阳两虚为治点,辅之以活血化瘀药物,其治疗效果均不够理想。如CN101700354B专利公开的治疗糖尿病的中药,其配方为:西洋参1-5、知母2-6份、石膏1-5份、苦瓜3-8份、蚕茧2-6份、黄芪1-5份、山药1-5份、生地1-5份、玄参1-5份、北沙参1-5份、麦冬1-5份、玉竹1-5份、黄精1-5份、天花粉1-5份、鸡内金1-5份、黄连1-5份、山萸肉1-5份、枸杞子2-7份、女贞子2-7份、淫羊藿1-5份;CN103751344A公开的治疗糖尿病的药物,其由有效成分和/或化学上可接受的载体组成,其有效成分由附子5-15份、肉桂1-5份、巴戟天5-15份制成,等等。At present, the treatment of diabetes at home and abroad is divided into two types: traditional Chinese medicine and western medicine. Western medicine mainly relies on insulin, which takes a long time to take and has many side effects, and microvascular lesions may occur; biguanide drugs have low curative effect and large side effects. Chinese medicine has a long history of treating diabetes in my country. In recent times, more and more traditional Chinese medicine prescriptions have been released to the world. However, looking at these technologies, most of them are aimed at solving the deficiency of both yin and yang in diabetes, supplemented by drugs for promoting blood circulation and removing blood stasis. , the therapeutic effect is not satisfactory. Such as the Chinese medicine for treating diabetes disclosed in CN101700354B patent, its formula is: 1-5 parts of American ginseng, 2-6 parts of Anemarrhena, 1-5 parts of gypsum, 3-8 parts of balsam pear, 2-6 parts of silkworm cocoons, 1-5 parts of astragalus, 1-5 parts of Chinese yam, 1-5 parts of raw land, 1-5 parts of Scrophulariaceae, 1-5 parts of Adenophora, 1-5 parts of Ophiopogon japonicus, 1-5 parts of Polygonatum Polygonatum, 1-5 parts of Polygonatum, 1-5 parts of Trichosanthum Fen 5 parts, 1-5 parts of gallinacea, 1-5 parts of coptis, 1-5 parts of cornus, 2-7 parts of medlar, 2-7 parts of privet fruit, 1-5 parts of epimedium; CN103751344A discloses A medicine for treating diabetes, which is composed of active ingredients and/or chemically acceptable carriers, and the active ingredients are made of 5-15 parts of aconite, 1-5 parts of cinnamon, 5-15 parts of Morinda officinalis, etc.
发明内容Contents of the invention
本发明针对现有技术的缺陷,提供一种用于治疗Ⅱ型糖尿病的组合药物,能够有效地治疗Ⅱ型糖尿病,治愈率高,复发率低。Aiming at the defects of the prior art, the invention provides a combination medicine for treating type Ⅱ diabetes, which can effectively treat type Ⅱ diabetes, has high cure rate and low recurrence rate.
实现上述目的所采取的技术方案是:一种用于治疗Ⅱ型糖尿病的组合药物,由下列重量份的药物制成:黄芪15-20份、人参15-20份、女贞子10-15份、枸杞子15-25份、焦白术10-15份、熟地15-20份、葛根15-20份、郁金8-10份、鸡内金10-15份、马齿苋8-10份、蒲公英8-10份、木香5-8份、地衣20-30份、白萝卜缨20-30份、红薯叶20-30份、柳叶15-20份、洋槐叶15-20份。The technical solution adopted to achieve the above object is: a combined medicine for treating type II diabetes, which is made of the following medicines in parts by weight: 15-20 parts of astragalus, 15-20 parts of ginseng, 10-15 parts of Ligustrum lucidum , 15-25 parts of medlar, 10-15 parts of Jiaobaizhu, 15-20 parts of Rehmannia glutinosa, 15-20 parts of kudzu root, 8-10 parts of turmeric, 10-15 parts of gallinaceous gold, 8-10 parts of purslane, 8-10 parts of dandelion, 5-8 parts of woody fragrance, 20-30 parts of lichen, 20-30 parts of white radish leaves, 20-30 parts of sweet potato leaves, 15-20 parts of willow leaves, 15-20 parts of acacia leaves.
所述用于治疗Ⅱ型糖尿病的组合药物,由下列重量份的药物制成:The combined medicine for treating type Ⅱ diabetes is made of the following medicines in parts by weight:
黄芪15份、人参15份、女贞子10份、枸杞子20份、焦白术10份、熟地15份、葛根15份、郁金10份、鸡内金15份、马齿苋10份、蒲公英10份、木香5份、地衣30份、白萝卜缨30份、红薯叶30份、柳叶20份、洋槐叶20份。本实施例的方案适用于初期Ⅱ型糖尿病患者。15 parts of astragalus, 15 parts of ginseng, 10 parts of Ligustrum lucidum, 20 parts of medlar, 10 parts of Jiaobaizhu, 15 parts of Rehmannia glutinosa, 15 parts of kudzu root, 10 parts of turmeric, 15 parts of gallinaceous gold, 10 parts of purslane, dandelion 10 parts, 5 parts of woody fragrance, 30 parts of lichen, 30 parts of white radish leaves, 30 parts of sweet potato leaves, 20 parts of willow leaves, and 20 parts of acacia leaves. The scheme of this embodiment is suitable for patients with early type Ⅱ diabetes.
所述用于治疗Ⅱ型糖尿病的组合药物,由下列重量份的药物制成:The combined medicine for treating type Ⅱ diabetes is made of the following medicines in parts by weight:
黄芪20份、人参20份、女贞子15份、枸杞子25份、焦白术10份、熟地20份、葛根20份、郁金8份、鸡内金10份、马齿苋8份、蒲公英8份、木香8份、地衣20份、白萝卜缨20份、红薯叶20份、柳叶15份、洋槐叶15份。 本实施例的方案适用于中后期Ⅱ型糖尿病患者。20 parts of astragalus, 20 parts of ginseng, 15 parts of Ligustrum lucidum, 25 parts of medlar, 10 parts of Jiaobaizhu, 20 parts of Rehmannia glutinosa, 20 parts of kudzu root, 8 parts of turmeric, 10 parts of gallinaceous gold, 8 parts of purslane, dandelion 8 parts, 8 parts of woody fragrance, 20 parts of lichen, 20 parts of white radish leaves, 20 parts of sweet potato leaves, 15 parts of willow leaves, and 15 parts of acacia leaves. The scheme of this embodiment is suitable for patients with type Ⅱ diabetes mellitus in the middle and late stages.
所述白萝卜缨和红薯叶于中秋节前采摘,柳叶和洋槐叶于清明节气以前采摘。The white radish leaves and sweet potato leaves are picked before the Mid-Autumn Festival, and the willow leaves and acacia leaves are picked before the Qingming Festival.
所述白萝卜缨、红薯叶、柳叶和洋槐叶采用低温烘干,烘干温度不超过50℃。The white radish leaves, sweet potato leaves, willow leaves and acacia leaves are dried at low temperature, and the drying temperature does not exceed 50°C.
所述白萝卜缨、红薯叶、柳叶和洋槐叶采用常温真空干燥。The white radish leaves, sweet potato leaves, willow leaves and acacia leaves are vacuum-dried at room temperature.
发明人结合传统认知,并通过对现代社会生活方式和结构的考察研究认为,随着生活的富裕,饮食失却节制,营养过剩,生活多静少动,消化吸收功能弱化,长时间处于精神紧张状态,导致肝肾不堪重负,各部脏器及血液系统瘀积化毒等生活状况是诱发糖尿病主要因素。久而久之瘀积益多,肌体虚弱日甚,积重难返,肥胖、浮肿引致本证,故而近时期以来糖尿病发病率越来越高,发病期不断提前。现代西医治疗长期用药唯求控制,且其副作用容易引起它病,患者生活在战战兢兢之中,精神负担愈来愈重。中医多以虚证论治,施以阴阳兼补为第一要义,或辅之以凉血补血、活血化瘀之药物,但不知瘀积不除,便秘不通,难以言补,只会带来新的瘀积。故而本发明由排除肌体及脏器内瘀积和血液内毒素入手,兼施以清热解毒、凉血补血、活血化瘀,疏肝解郁、正本清源,而后再行滋阴补阳,固本强末,以达标本并治之效果,赋患者以强健体魄。The inventor combines traditional cognition, and through investigation and research on the lifestyle and structure of modern society, believes that with the affluence of life, the diet loses restraint, overnutrition, life is more static and less active, digestion and absorption functions are weakened, and people are under mental stress for a long time Liver and kidney are overwhelmed, various organs and blood system are stagnant and detoxified, and other living conditions are the main factors that induce diabetes. Over time, more and more stasis accumulates, the body becomes weaker and heavier, and the accumulated weight is difficult to return. Obesity and edema cause this syndrome. Therefore, the incidence of diabetes has become higher and higher in recent times, and the onset period has been advancing. Modern Western medicine seeks to control long-term medication, and its side effects are likely to cause other diseases. Patients live in fear, and their mental burden is getting heavier and heavier. Traditional Chinese medicine mostly treats deficiency syndromes, with Yin and Yang tonic as the first priority, or supplemented with medicines that cool blood, nourish blood, activate blood and remove blood stasis. New stasis. Therefore, the present invention starts with eliminating blood stasis and blood endotoxins in the body and internal organs, and also performs heat-clearing and detoxifying, cooling blood and nourishing blood, promoting blood circulation and removing blood stasis, soothing the liver and relieving stagnation, rectifying the source, and then nourishing yin and nourishing yang, consolidating the root and strengthening the body. At the end, in order to achieve the effect of treating both symptoms and root causes, endow patients with a strong body.
本发明主要优点在于:Main advantage of the present invention is:
本发明的用于治疗Ⅱ型糖尿病的组合药物首先破瘀脱毒,清热解郁,除去瘀积,正本清源,由此谷精得以摄取、血液得以顺行,糖毒得以排除,胰岛素细胞得以再生,而后滋阴补阳,使患者肌体强健如初,糖尿病可得根治,故而能够收到见效快、疗程短治愈率高、复发率低的疗效。同时,该药物盖无毒副作用,并对携有肥胖症、高血压、高血脂、脂肪肝有奇特的疗效,还可收到减肥、美容,预防糖尿病的良好效果。The combined medicine for treating type Ⅱ diabetes of the present invention first breaks blood stasis and detoxifies, clears heat and relieves stagnation, removes blood stasis, and rectifies the root causes, so that glutinous rice can be taken in, blood can flow forward, sugar poison can be eliminated, and insulin cells can be regenerated. Then nourish yin and tonify yang, so that the patient's body is strong as before, and diabetes can be cured, so it can receive the curative effect of quick effect, short course of treatment, high cure rate and low recurrence rate. At the same time, the drug has no toxic and side effects, and has a unique curative effect on obesity, high blood pressure, high blood fat, and fatty liver. It can also receive good effects on weight loss, beauty, and diabetes prevention.
具体实施方式detailed description
本发明的用于治疗Ⅱ型糖尿病的组合药物,由下列重量份的药物制成:黄芪15-20份、人参15-20份、女贞子10-15份、枸杞子15-25份、焦白术10-15份、熟地15-20份、葛根15-20份、郁金8-10份、鸡内金10-15份、马齿苋8-10份、蒲公英8-10份、木香5-8份、地衣20-30份、白萝卜缨20-30份、红薯叶20-30份、柳叶15-20份、洋槐叶15-20份。 其中:白萝卜缨和红薯叶可于中秋节前采摘,柳叶和洋槐叶可于清明节气以前采摘,此几味嫩叶原料摘取后洗净阴干或低温烘干,烘干温度不超过50℃,或者常温真空干燥。诸药材备齐后分别粉碎,过200~300目筛制成细末直接使用或按常规方法制成水丸服用。服用时,每次9~15克,每日3次,饭后服用,30天为一个疗程。The combined medicine for treating type Ⅱ diabetes of the present invention is made of the following medicines in parts by weight: 15-20 parts of astragalus, 15-20 parts of ginseng, 10-15 parts of Ligustrum lucidum, 15-25 parts of wolfberry, coriander 10-15 parts of Atractylodes macrocephala, 15-20 parts of Rehmannia glutinosa, 15-20 parts of kudzu root, 8-10 parts of turmeric, 10-15 parts of gallinaceous gold, 8-10 parts of purslane, 8-10 parts of dandelion, and 5 parts of woody fragrance -8 parts, 20-30 parts of lichens, 20-30 parts of white radish leaves, 20-30 parts of sweet potato leaves, 15-20 parts of willow leaves, 15-20 parts of acacia leaves. Among them: white radish leaves and sweet potato leaves can be picked before the Mid-Autumn Festival, and willow leaves and acacia leaves can be picked before the Qingming solar term. ℃, or dry under vacuum at room temperature. After all the medicinal materials are prepared, they are crushed separately, passed through a 200-300 mesh sieve to make a fine powder and used directly or made into a water pill according to a conventional method. When taking it, take 9-15 grams each time, 3 times a day, after meals, and 30 days is a course of treatment.
实施例一Embodiment one
本发明的用于治疗Ⅱ型糖尿病的组合药物,其各组分的重量份配比可以是:黄芪15份、人参15份、女贞子10份、枸杞子15份、焦白术10份、熟地15份、葛根15份、郁金8份、鸡内金10份、马齿苋8份、蒲公英8份、木香5份、地衣20份、白萝卜缨20份、红薯叶20份、柳叶15份、洋槐叶15份。The combined medicine for treating type Ⅱ diabetes mellitus of the present invention, the weight ratio of each component can be: 15 parts of astragalus, 15 parts of ginseng, 10 parts of Ligustrum lucidum, 15 parts of medlar, 10 parts of Jiaobaizhu, Rehmannia glutinosa 15 parts, kudzu root 15 parts, turmeric 8 parts, gallinacea 10 parts, purslane 8 parts, dandelion 8 parts, woody 5 parts, lichen 20 parts, white radish leaves 20 parts, sweet potato leaves 20 parts, willow leaves 15 parts, 15 parts of acacia leaves.
实施例二Embodiment two
本发明的用于治疗Ⅱ型糖尿病的组合药物,其各组分的重量份配也还可以是:黄芪18份、人参18份、女贞子13份、枸杞子20份、焦白术13份、熟地18份、葛根18份、郁金9份、鸡内金13份、马齿苋9份、蒲公英6份、木香6份、地衣25份、白萝卜缨25份、红薯叶25份、柳叶17份、洋槐叶17份。The combined medicine for the treatment of type Ⅱ diabetes of the present invention, the parts by weight of its components can also be: 18 parts of astragalus, 18 parts of ginseng, 13 parts of Ligustrum lucidum, 20 parts of medlar, 13 parts of Jiaobaizhu, 18 parts of Rehmannia glutinosa, 18 parts of kudzu root, 9 parts of turmeric, 13 parts of gallinaceous gold, 9 parts of purslane, 6 parts of dandelion, 6 parts of woody fragrance, 25 parts of lichen, 25 parts of white radish sprouts, 25 parts of sweet potato leaves, willow 17 parts of leaves, 17 parts of acacia leaves.
实施例三Embodiment three
本发明的用于治疗Ⅱ型糖尿病的组合药物,其各组分的重量份配比还可以是:黄芪20份、人参20份、女贞子15份、枸杞子25份、焦白术15份、熟地20份、葛根20份、郁金10份、鸡内金15份、马齿苋10份、蒲公英10份、木香8份、地衣30份、白萝卜缨30份、红薯叶30份、柳叶20份、洋槐叶20份。The combined medicine for treating type Ⅱ diabetes mellitus of the present invention, the weight ratio of each component can also be: 20 parts of astragalus, 20 parts of ginseng, 15 parts of Ligustrum lucidum, 25 parts of medlar, 15 parts of Jiaobaizhu, 20 parts of Rehmannia glutinosa, 20 parts of kudzu root, 10 parts of turmeric, 15 parts of gallinacea, 10 parts of purslane, 10 parts of dandelion, 8 parts of woody fragrance, 30 parts of lichen, 30 parts of white radish sprouts, 30 parts of sweet potato leaves, willow 20 parts of leaves, 20 parts of acacia leaves.
实施例四Embodiment Four
黄芪15份、人参15份、女贞子10份、枸杞子20份、焦白术10份、熟地15份、葛根15份、郁金10份、鸡内金15份、马齿苋10份、蒲公英10份、木香5份、地衣30份、白萝卜缨30份、红薯叶30份、柳叶20份、洋槐叶20份。本实施例的方案适用于初期Ⅱ型糖尿病患者及肥胖症、高血脂、脂肪肝患者。15 parts of astragalus, 15 parts of ginseng, 10 parts of Ligustrum lucidum, 20 parts of medlar, 10 parts of Jiaobaizhu, 15 parts of Rehmannia glutinosa, 15 parts of kudzu root, 10 parts of turmeric, 15 parts of gallinaceous gold, 10 parts of purslane, dandelion 10 parts, 5 parts of woody fragrance, 30 parts of lichen, 30 parts of white radish leaves, 30 parts of sweet potato leaves, 20 parts of willow leaves, and 20 parts of acacia leaves. The protocol of this example is suitable for patients with early type Ⅱ diabetes and patients with obesity, hyperlipidemia and fatty liver.
实施例五Embodiment five
黄芪20份、人参20份、女贞子15份、枸杞子25份、焦白术10份、熟地20份、葛根20份、郁金8份、鸡内金10份、马齿苋8份、蒲公英8份、木香8份、地衣20份、白萝卜缨20份、红薯叶20份、柳叶15份、洋槐叶15份。 本实施例的方案适用于中、后期Ⅱ型糖尿病患者。20 parts of astragalus, 20 parts of ginseng, 15 parts of Ligustrum lucidum, 25 parts of medlar, 10 parts of Jiaobaizhu, 20 parts of Rehmannia glutinosa, 20 parts of kudzu root, 8 parts of turmeric, 10 parts of gallinaceous gold, 8 parts of purslane, dandelion 8 parts, 8 parts of woody fragrance, 20 parts of lichen, 20 parts of white radish leaves, 20 parts of sweet potato leaves, 15 parts of willow leaves, and 15 parts of acacia leaves. The scheme of this embodiment is suitable for patients with type Ⅱ diabetes mellitus in the middle and late stages.
本发明的药物组合自2012年以来在南阳医专第一附属医院临床试验,先后对128例糖尿病患者进行治疗,其中男性79例,占61.7%;女性49例,占48.3%;年龄最小的45岁,最大的79岁,平均年龄58岁;其中45-55岁43例,55-65岁52例,65岁以上33例;其中病程最短的6个月,最长的10年零3个月平均病程6年5个月。经本发明的药物治疗,糖尿病、高血压、高血脂等症状完全消失,且稳定无复发者112例,治愈率为87.5%;症状部分改善者8例,总有效率93.8%;治愈患者中停药1年以后有反复者8例,复发率为7.1%。The drug combination of the present invention has been clinically tested in the First Affiliated Hospital of Nanyang Medical College since 2012, and has treated 128 diabetic patients, including 79 males, accounting for 61.7%; 49 females, accounting for 48.3%; the youngest 45 years old, the oldest was 79 years old, and the average age was 58 years old; 43 cases were 45-55 years old, 52 cases were 55-65 years old, and 33 cases were over 65 years old; the shortest course of disease was 6 months, and the longest was 10 years and 3 months The average course of disease was 6 years and 5 months. After drug treatment of the present invention, symptoms such as diabetes, hypertension, and hyperlipidemia disappeared completely, and 112 cases were stable without recurrence, and the cure rate was 87.5%; 8 cases were partially improved by the symptoms, and the total effective rate was 93.8%; There were 8 cases of recurrence after 1 year of taking the medicine, and the recurrence rate was 7.1%.
典型病例Typical cases
病例1Case 1
陈某,男,36岁,南阳市唐河县个体老板,2012年3月6日初诊,自述糖尿病半年,时长头晕、头疼、四肢无力、没有精神,医院诊断空腹血糖11.0,无尿糖,糖化血红蛋白6.3,空腹胰岛素5.4,人体较胖。服药方法,每次10g,每日三次,早中晚饭后各服用一次,服药三个疗程后,经医院检查,各项指标恢复正常,自觉症状消失;继续服药六个月维持,每日早晚饭后各一次,体重减轻9kg,身心健康,回访三年,停药后各项指标再无反弹。Chen, male, 36 years old, self-employed owner in Tanghe County, Nanyang City, first visit on March 6, 2012, self-reported diabetes for half a year, dizziness, headache, limb weakness, lack of energy, hospital diagnosis of fasting blood sugar 11.0, no urine sugar, glycosylation Hemoglobin 6.3, fasting insulin 5.4, the body is fat. The method of taking the medicine is 10g each time, three times a day, once in the morning, lunch and dinner. After taking the medicine for three courses, after the hospital examination, all the indicators returned to normal, and the subjective symptoms disappeared; After each time, the weight loss was 9kg, and the body and mind were healthy. After three years of follow-up visits, all indicators did not rebound after drug withdrawal.
病例2Case 2
张某,女,62岁,南阳市内乡县退休干部,病人自述回忆患糖尿病已有7年许,自觉乏力,尿多尿频,腰疼并容易扭伤,层到医院检查尿糖++、空腹血糖8.7,未采取治疗措施,自我控制饮食维持。至2012年7月,病人突然出现视力模糊,手脚疼痛,心慌气短、浑身瘙痒、口腔溃疡、失眠乏力、皮疹等症状。经某市级医院检查确诊为Ⅱ型糖尿病,住院治疗,打胰岛素诺和灵每日2次,中午饭前半小时打诺和灵26个单位,下午饭前打诺和林22个单位,治疗期间并发症不减反增(尿蛋白++++、尿糖++++、心脏早搏、心律不齐、多发性肝肾囊肿、1/3牙齿脱落眼底浑浊。人黄黑而瘦,体重一个月内锐减20kg,乏力少言,失眠焦躁,失去治愈信心。2013年3月5日来院就诊,临床病体面色青灰,焦黑消瘦,低语懒言,舌诊舌体青紫而苍老,浊苔厚腻,口腥口臭。医嘱服用本发明的组合药物,每次15g,每日3次,早中晚饭后服用,停止注射胰岛素。服药40天后,病人饮水夜尿减少,低血糖症消失,余症消失。继续服药四个月后,临床症状消失,精神状态大有改善,检查理化指标糖化血红蛋白6.8,尿蛋白、脂肪肝消失,尿糖+,体重增加3kg,病人置于信心大增。医嘱继续服药维持,每次10g,每日早晚各1次,服用4个疗程后,经复查,病人各项理化指标正常,视力、心脏等恢复正常,经B超检查,肝肾囊肿消失,身体恢复健康。回访三年,再无反复。Zhang, female, 62 years old, a retired cadre in Neixiang County, Nanyang City. The patient reported that she had been suffering from diabetes for about 7 years. She felt weak, had frequent urination, low back pain and easy sprains. She went to the hospital to check urine sugar++ and fasting blood sugar. 8.7, no treatment measures are taken, and self-control diet is maintained. Until July 2012, the patient suddenly developed symptoms such as blurred vision, pain in hands and feet, palpitation, shortness of breath, itching all over the body, mouth ulcers, insomnia, fatigue, and rash. Diagnosed with type 2 diabetes by a city-level hospital, hospitalized, taking insulin Novolin twice a day, 26 units of Novolin half an hour before lunch, and 22 units of Novolin before meals in the afternoon. Complications did not decrease but increased (urinary protein ++++, urine sugar ++++, premature heartbeat, arrhythmia, multiple hepatic and renal cysts, 1/3 tooth loss and cloudy eyes. The person is yellow and black and thin, weighing one Within a month, she lost 20kg sharply, lacked energy and speech, insomnia and anxiety, and lost confidence in healing. On March 5, 2013, she came to the hospital for treatment. The clinical body was blue and gray, scorched and emaciated, whispering and lazy. , fishy mouth and bad breath. The doctor's advice is to take the combination medicine of the present invention, each 15g, every day 3 times, take after morning, noon and dinner, and stop injecting insulin. After taking the medicine for 40 days, the patient's drinking water and nocturia decreased, hypoglycemia disappeared, and the remaining symptoms disappeared After continuing to take the medicine for four months, the clinical symptoms disappeared, and the mental state was greatly improved. The physical and chemical indicators of glycosylated hemoglobin were 6.8, urine protein and fatty liver disappeared, urine sugar was +, and the weight increased by 3kg. The patient's confidence was greatly increased. The doctor ordered to continue taking medicine Maintenance, 10g each time, once a day in the morning and evening, after taking 4 courses of treatment, after reexamination, the patient's physical and chemical indicators were normal, vision, heart, etc. returned to normal, after B-ultrasound examination, liver and kidney cysts disappeared, and the body returned to health. Return visit for three years, no repeat.
病例3Case 3
何某,男,72岁,南阳市南召县农民,2014年8月2日前来就诊,自述糖尿病10年,自觉症状乏力,口干口渴,尿多尿频,并伴有高血压、高血脂症,人体面容憔悴黑瘦,精神疲惫,压力沉重,长期服用口服胰岛素、二甲双胍等降糖药物,效果很差。服用本发明的组合药物,每次15g,每日3次,早中晚饭后各服一次。连服三个疗程后,口干口渴、尿多尿频症状减轻,血压恢复正常;继续服药三个疗程,经医院检查,各项指标恢复正常,自觉症状全部消失;再服药六个月维持,每次10g,每日2次,早晚饭后各一次,回访三年,面色光润,身心健康,停药后各项指标再无反弹。He Mou, male, 72 years old, a farmer in Nanzhao County, Nanyang City, came to see a doctor on August 2, 2014. He reported diabetes for 10 years, subjective symptoms of fatigue, dry mouth and thirst, frequent urination, high blood pressure, and hyperlipidemia. The human body is haggard, black and thin, mentally exhausted, and under heavy pressure. Long-term use of oral insulin, metformin and other hypoglycemic drugs has poor effects. Take the combination medicine of the present invention, each 15g, every day 3 times, respectively obey once in the morning, middle and evening meals. After taking three courses of treatment, the symptoms of dry mouth, thirst, polyuria and frequent urination were alleviated, and blood pressure returned to normal; after taking the medicine for three courses, all indicators returned to normal after hospital examination, and all the subjective symptoms disappeared; 10g each time, 2 times a day, once in the morning and evening after meals. After a follow-up visit for three years, her complexion was radiant, her body and mind were healthy, and all indicators did not rebound after stopping the drug.
病例4Case 4
李某,男,49岁,南阳市卧龙区个体商户,2012年7月9日前来医院求治,自述身体肥胖已有7年,胸闷,乏力,坐卧皆喘息不停,胸部时常疼痛感,严重影响劳作。临床检查,身高1.68m,体重106.5kg,并有高血压、高血脂、脂肪肝、浮肿等症。医嘱服用本发明的组合药物,每次15g,每日3次,早中晚饭后服用,并停食油腻、酒水,服药30天后,体重减少4.2kg,喘息、胸部疼痛等自觉症状消失;继续服药二个疗程,经检查体重再减15kg,乏力、高血压、高血脂、脂肪肝、浮肿等症状消失,活动自如。医嘱继续服药,每次10g,每日早晚饭后各一次,限食油腻,忌饮酒水;再服六个疗程,经检查,体重减至72kg,体态正常,精神复初,劳作有力,精神矍铄,高兴非常;一年后回访,体重再减至67kg,且再无反弹。Li, male, 49 years old, a self-employed merchant in Wolong District, Nanyang City, came to the hospital for treatment on July 9, 2012, and reported that he had been obese for 7 years, with chest tightness, fatigue, wheezing when sitting and lying down, and frequent chest pains, severe affect labor. Clinical examination, height 1.68m, weight 106.5kg, and hypertension, hyperlipidemia, fatty liver, edema embolism. Take the combination medicine of the present invention according to the doctor's order, each 15g, 3 times a day, take it after morning, noon and dinner, and stop eating greasy, alcoholic beverages. After taking the medicine for 30 days, the body weight decreased by 4.2kg, and the subjective symptoms such as wheezing and chest pain disappeared; After a course of treatment, the body weight was reduced by 15kg after examination, and symptoms such as fatigue, high blood pressure, high blood fat, fatty liver, and edema disappeared, and she moved freely. The doctor ordered to continue to take the medicine, 10g each time, once a day after breakfast and dinner, limit greasy food, avoid drinking alcohol and water; after another six courses of treatment, after examination, the weight was reduced to 72kg, the body was normal, the spirit was restored, the work was vigorous, and the spirit was hale and hearty , very happy; a return visit a year later, the weight was reduced to 67kg, and there was no rebound.
最后说明的是,以上实施例仅用以说明本发明的技术方案而非限制,本领域普通技术人员对本发明的技术方案所做的其他修改或者等同替换,只要不脱离本发明技术方案的精神和范围,均应涵盖在本发明的权利要求范围当中。Finally, it is noted that the above embodiments are only used to illustrate the technical solution of the present invention without limitation, other modifications or equivalent replacements made by those skilled in the art to the technical solution of the present invention, as long as they do not depart from the spirit and spirit of the technical solution of the present invention All should be included in the scope of the claims of the present invention.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710076490.7A CN106606744A (en) | 2017-02-13 | 2017-02-13 | Combination medicament for treating type 2 diabetes mellitus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710076490.7A CN106606744A (en) | 2017-02-13 | 2017-02-13 | Combination medicament for treating type 2 diabetes mellitus |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106606744A true CN106606744A (en) | 2017-05-03 |
Family
ID=58636517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710076490.7A Pending CN106606744A (en) | 2017-02-13 | 2017-02-13 | Combination medicament for treating type 2 diabetes mellitus |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106606744A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108815264A (en) * | 2018-07-16 | 2018-11-16 | 山东景仲生物科技有限公司 | A kind of reparation liquid of conditioning subhealthy state and chronic disease |
-
2017
- 2017-02-13 CN CN201710076490.7A patent/CN106606744A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108815264A (en) * | 2018-07-16 | 2018-11-16 | 山东景仲生物科技有限公司 | A kind of reparation liquid of conditioning subhealthy state and chronic disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101396531B (en) | Traditional Chinese medicine for treating allergic purpura | |
CN104208532B (en) | A kind of medicine for treating erythrodermic psoriasis | |
CN106606744A (en) | Combination medicament for treating type 2 diabetes mellitus | |
CN102988892B (en) | Medicament for treating hysteromyoma and ovarian cysts | |
CN102940757A (en) | Medicine composition for treating diabetic foot | |
CN102580030A (en) | External traditional Chinese medicine composition having effect of reducing blood sugar, preparation prepared from the external traditional Chinese medicine composition, and their preparation method | |
CN102283993B (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
CN115779046B (en) | A Chinese medicine composition, Chinese medicine preparation and application for preventing and treating diabetes | |
CN105232754A (en) | Medicine for treating type-II diabetes | |
CN104306948A (en) | Medicament composition for treating gouty arthritis | |
CN114796420B (en) | A traditional Chinese medicine composition for treating non-valvular atrial fibrillation and its preparation and application | |
CN105125814B (en) | It is a kind of to treat chronic renal failure III, the Chinese medicine composition of IV phase | |
CN103599386B (en) | A kind of Chinese medicine composition for diabetes | |
CN116211991B (en) | A Chinese medicine composition for treating primary dysmenorrhea | |
CN1132603C (en) | Compound Wuduqing capsule of blister beetle | |
CN102940671B (en) | Medicine composition for treating diabetic foot | |
CN104815194A (en) | Method for preparing medicine for treating diabetic nephropathy | |
CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications | |
CN107468849A (en) | A kind of medicine for treating chronic renal failure and preparation method thereof | |
CN101112553A (en) | Oral Chinese traditional medicine composition for treating chronic enteritis | |
CN118593615A (en) | A Yishen Guyuan Jian Chinese medicine composition for delaying renal fibrosis | |
CN118001362A (en) | Traditional Chinese medicine composition, preparation and application for treating qi deficiency and blood stasis type coronary heart disease angina or PCI postoperative angina | |
CN111544544A (en) | A traditional Chinese medicine prescription for the treatment of elderly type 2 diabetes mellitus | |
CN117771329A (en) | Traditional Chinese medicine composition for treating chronic kidney disease and application thereof | |
CN117695346A (en) | Medicine for treating arthritis caused by gout |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170503 |